Pemphigus vulgaris is an intraepidermal autoimmune mucocutaneous blistering disease whose etiopathogenesis includes various trigger factors, i.e., drugs and malignancies. We present a case of malignancy-exacerbated pemphigus vulgaris which required a careful diagnostic process in order to rule out paraneoplastic pemphigus, along with the challenges posed by the need of treating both cutaneous and oncologic diseases. Possible post-operative complications post-poned the start of first-line immunosuppressive treatment of pemphigus. Moreover, the infective risks had to be minimized during the peak of the COVID-19 pandemic in Italy. Intravenous immunoglobulins were chosen as “bridge” therapy before the tumor surgical excision, followed by rituximab in post-operative phase.

Case Report: Management of Malignancy-Exacerbated Pemphigus Vulgaris During COVID-19 Pandemic / Corra A.; Cammelli F.; Quintarelli L.; Barbato G.; Le Rose O.; Salemme A.; Di Zenzo G.; Coratti F.; Verdelli A.; Aimo C.; Mariotti E.B.; Bianchi B.; Cianchi F.; Caproni M.. - In: FRONTIERS IN MEDICINE. - ISSN 2296-858X. - ELETTRONICO. - 8:(2021), pp. 0-0. [10.3389/fmed.2021.708284]

Case Report: Management of Malignancy-Exacerbated Pemphigus Vulgaris During COVID-19 Pandemic

Cammelli F.;Quintarelli L.;Coratti F.;Verdelli A.;Aimo C.;Mariotti E. B.;Cianchi F.;Caproni M.
2021

Abstract

Pemphigus vulgaris is an intraepidermal autoimmune mucocutaneous blistering disease whose etiopathogenesis includes various trigger factors, i.e., drugs and malignancies. We present a case of malignancy-exacerbated pemphigus vulgaris which required a careful diagnostic process in order to rule out paraneoplastic pemphigus, along with the challenges posed by the need of treating both cutaneous and oncologic diseases. Possible post-operative complications post-poned the start of first-line immunosuppressive treatment of pemphigus. Moreover, the infective risks had to be minimized during the peak of the COVID-19 pandemic in Italy. Intravenous immunoglobulins were chosen as “bridge” therapy before the tumor surgical excision, followed by rituximab in post-operative phase.
2021
8
0
0
Corra A.; Cammelli F.; Quintarelli L.; Barbato G.; Le Rose O.; Salemme A.; Di Zenzo G.; Coratti F.; Verdelli A.; Aimo C.; Mariotti E.B.; Bianchi B.; C...espandi
File in questo prodotto:
File Dimensione Formato  
fmed-08-708284.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 1.92 MB
Formato Adobe PDF
1.92 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1259031
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact